This short historical abstract describes development status in 2004. It provides no MS trial results and does not establish an approved or effective MS treatment.
IDrugs. 2004 Feb;7(2):166-72
Lasky J.
Tulane University Health Sciences Center, 1430 Tulane Avenue, SL-9, New Orleans, LA 70112, USA.
Pirfenidone, an antifibrotic tissue growth antagonist, is in development for the potential treatment of fibrotic diseases including renal, liver and pulmonary fibrosis and for multiple sclerosis.
Source details
Author: Lasky J.
Archive capture: . This is not a medical review date.